{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogen+Activity&page=2", "query": { "condition": "Estrogen Activity", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Estrogen+Activity&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T08:35:12.185Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06428396", "title": "Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-11-27", "completion_date": "2028-12-25", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 14, "location_summary": "Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428396" }, { "nct_id": "NCT03455270", "title": "G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Ductal, Breast", "Breast Cancer Female", "Breast Neoplasm", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "G1T48", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 107, "start_date": "2018-05-09", "completion_date": "2022-09-29", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 6, "location_summary": "Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03455270" }, { "nct_id": "NCT03106077", "title": "Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Negative", "Folate Receptor Alpha Positive", "HER2/Neu Negative", "Progesterone Receptor Negative", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2017-06-05", "completion_date": "2019-10-01", "has_results": true, "last_update_posted_date": "2020-12-02", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03106077" }, { "nct_id": "NCT00420342", "title": "Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postmenopause", "Hypertension", "Pre-Hypertension" ], "interventions": [ { "name": "Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)", "type": "DRUG" }, { "name": "SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "45 Years to 65 Years · Female only" }, "enrollment_count": 92, "start_date": "2007-01", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2015-06-02", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 9, "location_summary": "Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Paw Paw", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420342" }, { "nct_id": "NCT05080842", "title": "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AC682", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accutar Biotechnology Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-11-12", "completion_date": "2024-04-04", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080842" }, { "nct_id": "NCT02684032", "title": "A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 141, "start_date": "2016-06-14", "completion_date": "2022-01-19", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02684032" }, { "nct_id": "NCT00001770", "title": "Progestin (Progesterone-Like Hormones) Induced Dysphoria (Depressed Mood, Irritability, Anxiety)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Depressive Disorder", "Mood Disorder", "Psychomotor Agitation" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 50, "start_date": "1998-03", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001770" }, { "nct_id": "NCT01124695", "title": "Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2011-01-07", "completion_date": "2022-12", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 292, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 203 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Marysville", "state": "California" }, { "city": "Merced", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01124695" }, { "nct_id": "NCT00342095", "title": "Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Environmental Health Sciences (NIEHS)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 640, "start_date": "1996-12-17", "completion_date": "2007-03-07", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 6, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina • Greenville, North Carolina + 3 more", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00342095" }, { "nct_id": "NCT05654532", "title": "Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AC699", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accutar Biotechnology Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2022-12-29", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-23T08:35:12.185Z", "location_count": 9, "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05654532" } ] }